Industry Signals
EW$101.85-1.95%
MDT$99.94-0.67%
ABT$103.00-0.84%
BSX$41.98-2.35%
SYK$310.00-0.98%
ZBH$101.10-0.36%
RMD$235.63-0.53%
ICHR$27.28-15.15%
Previous close · Nov 22

Industry

Company news, device launches, earnings, and market intelligence

10 articles about Abbott
CVB
news·2 days ago·Cardiovascular Business

Self-expanding TAVR valves from Medtronic, Abbott consistently linked to positive outcomes

Self-expanding TAVR valves from Medtronic and Abbott demonstrate consistent positive clinical outcomes in comparative analyses. The findings support the sustained performance profile of these platforms in transcatheter aortic valve replacement procedures.

Digest: These data reinforce operator confidence in self-expanding valve technology and may influence device selection strategies among interventional cardiologists, particularly in anatomies where self-expanding platforms offer theoretical advantages.

TAVRMedtronicAbbottMarketRead original
CVB
trial·3 days ago·Cardiovascular Business

Abbott kicks off new research on software-guided, balloon-expandable TAVR system

Abbott has initiated new research on a software-guided, balloon-expandable transcatheter aortic valve replacement system. No specific clinical data or trial endpoints were provided in the article content.

Digest: Abbott's entry into balloon-expandable TAVR with software guidance could challenge Edwards and Medtronic's market dominance and potentially improve procedural precision and outcomes.

TAVRAbbottTrialImagingRead original
DIC
trial·17 days ago·Diagnostic & Interventional Cardiology

Abbott Begins Enrollment in Global Trial of Investigational Mitral Valve Replacement System

Abbott has initiated enrollment in a global clinical trial evaluating its investigational transcatheter mitral valve replacement system. No specific enrollment targets, trial design details, or timeline information were provided in the article.

Digest: This represents Abbott's strategic entry into the competitive TMVR market, currently dominated by early-stage investigational devices from Edwards and Medtronic.

TMVRAbbottTrialRead original
DIC
trial·19 days ago·Diagnostic & Interventional Cardiology

Abbott Announces 30-day Clinical Trial Results for Coronary Intravascular Lithotripsy System

Abbott announced 30-day results from a clinical trial evaluating its coronary intravascular lithotripsy (IVL) system for treating calcified coronary artery lesions. The trial assessed safety and performance of the device in modifying severely calcified coronary lesions prior to stenting.

Digest: This represents Abbott's entry into the coronary IVL space, a market currently dominated by Shockwave Medical, and could expand treatment options for complex calcified coronary disease that structural heart teams encounter in TAVR and other transcatheter procedures.

AbbottTrialFDARead original
CVB
trial·23 days ago·Cardiovascular Business

Abbott now enrolling patients for new research on Cephea mitral valve replacement device

Abbott has initiated patient enrollment for a new clinical study evaluating the Cephea transcatheter mitral valve replacement system. The trial represents continued development of Abbott's TMVR platform for treating mitral valve disease.

Digest: This enrollment milestone advances Abbott's competitive position in the developing TMVR market, where multiple platforms are vying for clinical validation and eventual regulatory approval.

TMVRAbbottTrialRead original
Diagnostic & Interventional Cardiology
regulatory·25 days ago·Diagnostic & Interventional Cardiology

PVL Occluder Receives FDA Clearance

Abbott received FDA approval for the Amplatzer Paraclose PVL Occluder, the first transcatheter device specifically designed to treat paravalvular leak following surgical valve replacement. The approval was supported by the PARADIGM study, a prospective multicenter trial of 200 patients demonstrating effective minimally invasive closure of PVL as an alternative to repeat open-heart surgery.

Digest: This approval addresses a significant unmet need for the 5-17% of surgical valve replacement patients who develop paravalvular leak, providing the first purpose-built transcatheter solution to avoid repeat cardiac surgery.

FDAAbbottSurgicalMinimally InvasiveRead original
CVB
regulatory·3 months ago·Cardiovascular Business

FDA confirms new recall for Impella heart pump accessories

The FDA has confirmed a new recall affecting accessories used with Abiomed's Impella percutaneous ventricular assist device system. Specific details regarding the affected accessory components, reason for recall, and adverse event data were not provided in the available article content.

Digest: Impella devices are widely used for hemodynamic support during high-risk PCI and cardiogenic shock management, making any recall of associated accessories clinically relevant for procedural safety and device availability.

FDAAbbottHigh RiskRead original
Diagnostic & Interventional Cardiology
trial·4 months ago·Diagnostic & Interventional Cardiology

Clinical Study to Look at Real-World Use of Transcatheter Edge-to-Edge Repair System for Leaky Tricuspid Heart Valve

Abbott has initiated the Treat TR study, a post-market study enrolling approximately 1,000 patients across up to 100 sites in the U.S., Canada, and Europe to evaluate the safety and performance of the TriClip transcatheter edge-to-edge repair system for tricuspid regurgitation in real-world settings. Patients will be followed for five years, with a sub-study examining the system's potential to reverse cardiac remodeling.

Digest: This large-scale real-world evidence study will provide critical post-market performance data for TriClip TEER, informing adoption decisions and potentially expanding treatment paradigms for TR in clinical practice.

TTVRAbbottTrialMinimally InvasiveRead original
CVB
industry·4 months ago·Cardiovascular Business

Abbott gathering real-world data on FDA-approved TriClip system

Abbott is collecting real-world data on its TriClip transcatheter tricuspid valve repair system following FDA approval. The post-market data collection will provide insights into clinical outcomes and device performance outside of controlled trial settings.

Digest: Real-world evidence will be critical for understanding TriClip performance in broader patient populations and supporting clinical adoption in the emerging transcatheter tricuspid repair market.

TTVRAbbottFDARegulatoryRead original
Diagnostic & Interventional Cardiology
news·about 7 years ago·Diagnostic & Interventional Cardiology

Highlighting Innovation at the University of Colorado Hospital Cardiology Program

University of Colorado Hospital's Heart and Vascular Center performs approximately 3,000 interventional and structural heart procedures annually, including complex PCI with hemodynamic support and transcatheter mitral valve repair. The program has participated in pivotal trials for structural heart devices and performs 25-50 chronic total occlusion procedures and 50 Impella-supported high-risk PCI cases per year.

Digest: This academic center's experience with MitraClip procedures, complex high-risk PCI, and participation in pivotal device trials provides insights into advanced structural heart program development and procedural volumes at high-performing institutions.

TMVRAbbottHigh RiskImagingRead original